Oxazepam Shortage: What Providers and Prescribers Need to Know in 2026

Oxazepam (formerly branded as Serax) is a short-to-intermediate acting benzodiazepine that occupies a specific clinical niche — particularly valued for its glucuronidation metabolism, absence of active metabolites, and relative safety in hepatic impairment and elderly patients. Clinicians prescribing Oxazepam in 2026 are encountering patient reports of pharmacy stock-outs with increasing frequency. This briefing provides a structured overview of the supply landscape, clinical management strategies, and substitution guidance.

Current Supply Landscape (2026)

Oxazepam is not listed on the FDA's Drug Shortage Database as of 2026. The drug is manufactured by multiple generic companies including Sandoz, IVAX, and Apotex, and national distribution continues. However, at the individual pharmacy level, clinicians are observing a pattern consistent with recurring localized micro-shortages:

• Oxazepam has a smaller prescribing volume than lorazepam, alprazolam, or diazepam, meaning pharmacies maintain proportionally lower par levels
• DEA Schedule IV status constrains annual production — quotas cannot be rapidly adjusted when demand increases
• Brand-name Serax has been discontinued; the generic-only market is more vulnerable to single-manufacturer disruptions
• Post-pandemic elevated demand for the entire benzodiazepine class has not fully resolved

Clinical Context: Why Oxazepam Is Specifically Prescribed

When evaluating substitution options, it is essential to understand the clinical rationale for the original Oxazepam prescription. The drug is FDA-approved for:

• Anxiety disorders and short-term relief of anxiety symptoms
• Anxiety associated with major depressive disorder
• Alcohol withdrawal syndrome management

Oxazepam's key pharmacological differentiators:

• Glucuronidation metabolism: Bypasses CYP450; safer in hepatic impairment and cirrhosis
• No active metabolites: Reduces accumulation risk in elderly patients and those with renal impairment
• Slower onset: 30-60 minutes to effect; lower abuse liability compared to faster-onset benzodiazepines
• Intermediate half-life: Approximately 8-12 hours; no active metabolites means predictable clearance

Substitution Guidance by Clinical Indication

Disclaimer: Benzodiazepine equivalency data are estimates. Clinical judgment, patient-specific factors (age, hepatic function, renal function, duration of use, concurrent medications), and individual response must guide all dose conversions.

For Anxiety Management

• Preferred substitute:
• Lorazepam (Ativan): Most pharmacologically similar (also glucuronidated, no active metabolites). Approximate equivalence: 1 mg lorazepam ≈ 15 mg oxazepam. Faster onset may increase patient-perceived potency; counsel accordingly.
• Clonazepam: Longer-acting option with less interdose anxiety. Approximately 0.5 mg clonazepam ≈ 15 mg oxazepam (use caution with this conversion). CYP3A4 metabolism; consider in patients without significant hepatic or drug-interaction concerns.

For Alcohol Withdrawal Management

• Diazepam: Long-acting; preferred for front-loading in uncomplicated alcohol withdrawal. Approximate equivalence: 5 mg diazepam ≈ 10 mg oxazepam. Caution: not appropriate in significant hepatic impairment due to CYP450 metabolism and active metabolite accumulation.
• Chlordiazepoxide: ASAM-supported alternative for alcohol withdrawal front-loading. Approximate equivalence: 25 mg chlordiazepoxide ≈ 15 mg oxazepam. Same hepatic metabolism caveat as diazepam.
• Lorazepam: Preferred for alcohol withdrawal in patients with hepatic impairment — same glucuronidation pathway as oxazepam. Can also be administered IV in severe withdrawal.

Special Populations: Where Oxazepam Substitution Is Most Complex

Hepatic impairment / cirrhosis: If Oxazepam was prescribed specifically for this reason, the only clinically appropriate benzodiazepine substitutes are those that are also glucuronidated: lorazepam and temazepam. Long-acting CYP450-metabolized benzodiazepines (diazepam, chlordiazepoxide, clonazepam) are inappropriate.

Elderly patients: Oxazepam's no-active-metabolite profile is critical. If substituting, lorazepam at conservative doses is the most appropriate option. Avoid diazepam and other long-acting benzodiazepines in the elderly due to accumulation and fall risk.

Prescribing and Documentation Best Practices

• Document the clinical rationale when substituting (e.g., "Oxazepam unavailable — switching to lorazepam per equivalent dosing")
• Counsel patients explicitly that the substitute is not the same medication — dose, frequency, and side effect profiles differ
• Arrange a follow-up within 1-2 weeks when switching benzodiazepines to monitor for efficacy and tolerability
• Write prescriptions 1-2 weeks before the expected refill date to allow time to locate Oxazepam if stock is limited

medfinder for Providers

medfinder for providers helps clinical teams locate specific medications at pharmacies near your patients. Before writing a substitute prescription, consider using medfinder to determine whether Oxazepam is available at a nearby pharmacy — this can save the clinical complexity of a benzodiazepine switch entirely.